BIRC3 and colorectal carcinoma: Moreover, the upregulation of BIRC3 reduces the responsiveness of CRC cells to 5-fluorouracil (5-Fu), suggesting that targeting BIRC3 may offer a promising strategy to alleviate chemotherapy resistance in advanced CRC (99).